General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

BioNTech Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including ...

After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered COVID-19 vaccine Comirnaty, the German ...

Lawyers for Pfizer and BioNTech claimed that the 'technical contribution ... Required cookies to perform essential website ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

https://www.tipranks.com/news/the-fly/si-bone-price-target-raised-to-20-from-19-at-needham BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a ...

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster ...

2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof.

BioNTech SE ( (BNTX)) has provided an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly ...